ATS 2019 Virtual Final Program

9:30 Lessons from the Heart: Clinical and Biochemical Markers of Chronic Pulmonary Hypertension in Formerly Premature Infants E.D. Austin, MD, MSc, Nashville, TN 9:50 What to Do About All That RAGE: The Inflammation Story Continues J. Benjamin, MD, MPH, Nashville, TN 10:10 Neonatal Immunology: T-Cell CD31 Expression is a Biomarker for BPD G.S. Pryhuber, MD, Rochester, NY 10:30 Respiratory Medications in the NICU and Beyond J. Greenberg, MD, Cincinnati, OH 10:50 Physiologic Outcomes of ELGANs at 1 Year of Age J.A. Voynow, MD, Richmond, VA 11:10 Where Do We Go From Here? P.E. Moore, MD, ATSF, Nashville, TN BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM CME Credits Available: 2 B7 GLOBAL PERSPECTIVES ON CLIMATE CHANGE: IMPACT ON SUSCEPTIBLE POPULATIONS AND LOW-INCOME COUNTRIES Assemblies on Environmental, Occupational and Population Health; Allergy, Immunology and Inflammation; Behavioral Science and Health Services Research; Nursing; Pediatrics; Pulmonary Infections and Tuberculosis 9:15 a.m. - 11:15 a.m. OMNI DALLAS DOWNTOWN Trinity Ballroom 4/8 (Level 3) Target Audience Scientists, clinicians (pulmonology, cardiology, pediatrics, gerontology), public health/global health practitioners, and trainees interested in environmental impact of health Objectives At the conclusion of this session, the participant will be able to: • understand the recent evidence on the degree of global climate change, and worldwide actions to stop it; • gain the knowledge about the health impacts of climate change, particularly among vulnerable populations including the elderly and children; • encourage ATS members and others to become involved and respond to the health challenges posed by climate change through influencing policy makers. Climate change impacts individuals around the world especially when adaptation to climate change is a matter of survival for low and middle-income countries. Vulnerability to climate change is not the same for different countries and communities. The main objectives of this symposium are to present a global perspective on the health effects of global climate change. The degree of climate change worldwide changes according to vulnerability of geographic locations such as Arctic, Antarctic, Africa, Middle East, Mediterranean, Asia and Island States. This session will present recent developments in our understanding of the health effects of climate change among vulnerable countries and individuals. Leading scientists will address mechanisms, vulnerability and risk factors of climate change. Chairing: J.R. Balmes, MD, ATSF, San Francisco, CA M.B. Rice, MD, MPH, Boston, MA H. Bayram, MD, PhD, ATSF, Istanbul, Turkey 9:15 Climate Change: How Bad Is It? Is There Sufficient Action to Mitigate Its Effects? W. Abdalati, PhD, Boulder, CO 9:35 An Overview of Health Impacts of Climate Change M. Akpinar-Elci, MD, MPH, ATSF, Norfork, VA 9:55 Lung Health in an Era of Climate Change and Dust Storms M. Mirsaeidi, MD, Miami, FL 10:15 Does Age Matter in Climate Change? I. Annesi-Maesano, MD, PhD, DSc, Paris, France 10:35 Is the Worst for the Poorest?: Vulnerable Regions and Countries H. Bayram, MD, PhD, ATSF, Istanbul, Turkey 10:55 Does It Really Matter for Developed World? K.E. Pinkerton, PhD, Davis, CA BEHAVIORAL • CLINICAL SCIENTIFIC SYMPOSIUM CME Credits Available: 2 MOC Points Available: 2 B8 ENSURING BROAD DISSEMINATION AND EQUITABLE ACCESS TO LUNG CANCER SCREENING: CHALLENGES AND OPPORTUNITIES Assemblies on Thoracic Oncology; Behavioral Science and Health Services Research; Nursing 9:15 a.m. - 11:15 a.m. KBHCCD Ballroom A One (Level 2) Target Audience clinicians, patients, policy makers, patient advocacy groups, researchers interested in lung cancer screening and reducing disparities in lung health Objectives At the conclusion of this session, the participant will be able to: • learn new findings about barriers to equitable access to lung cancer screening; • more appropriately identify and refer candidates for lung cancer screening; • gain new strategies to overcome disparities in access to lung cancer screening. Annual lung cancer screening with low dose CT is one of the few public health interventions proven to reduce lung cancer mortality, yet it is markedly underutilized, with national screening rates under 5% among eligible individuals. There is particular concern that socioeconomically disadvantaged individuals, including those in inner cities as well as rural areas, are at risk for further disparities in lung cancer outcomes if screening is not disseminated broadly. This session will explore barriers faced by patients, clinicians, and systems ATS 2019 • Dallas, TX 126 MONDAY • MAY 20